dSILVER
The Next Evolution
Our digital silver (dSilver) technology builds upon our unique digital plasmonic nanobubble (dPNB) approach by eliminating the need for a high-power excitation laser, thereby slashing instrumentation costs by an order of magnitude, while maintaining single-particle detection, ease of use, and multiplex capability.
A broad societal benefit
Avsana’s dSilver methodology provides an ultrasensitive, multiplexed diagnostic capability enabling the detection of low-abundance blood-based biomarkers (BBMs) through a simple, low-cost, scalable assay suitable for decentralized environments. Operable without specialized technicians or costly lab infrastructure, this technology democratizes access to BBM testing, facilitating population-scale screening in rural areas, community clinics, and low-resource settings, for a variety of neurodegenerative and other diseases.
taking the next step
dSilver builds on outcomes from a completed NIAID Phase I STTR project, which developed a highly sensitive prototype assay for respiratory diagnostics using dPNB technology. The dPNB assay achieved a 100-fold improvement in sensitivity over standard PCR formats and was repurposed for protein detection, attaining attomolar limits of detection. Now, by eliminating the need for the high-power laser excitation that was used under dPNB, dSilver drastically reduces cost, providing a solution that is highly sensitive, easy to use, cost-effective, with rapid turnaround and mutliplex capability.
Fast
Results within 20 minutes
High throughput
60 samples per hour capacity
Low limit of detection
Single-particle detection limit
Highly specific
Comparable to RT-PCR
Cost-effective
Under $15 per test
Multiplex potential
Testing expandable to other viral pathogens